There is a crucial need for alternatives to native vein or artery for vascular surgery. The clinical efficacy of synthetic, allogeneic or xenogeneic vessels has been limited by thrombosis, rejection, chronic inflammation and poor mechanical properties. Using adult human fibroblasts extracted from skin biopsies harvested from individuals with advanced cardiovascular disease, we constructed tissue-engineered blood vessels (TEBVs) that serve as arterial bypass grafts in long-term animal models. These TEBVs have mechanical properties similar to human blood vessels, without relying upon synthetic or exogenous scaffolding. The TEBVs are antithrombogenic and mechanically stable for 8 months in vivo. Histological analysis showed complete tissue integration and formation of vasa vasorum. The endothelium was confluent and positive for von Willebrand factor. A smooth muscle-specific a-actin-positive cell population developed within the TEBV, suggesting regeneration of a vascular media. Electron microscopy showed an endothelial basement membrane, elastogenesis and a complex collagen network. These results indicate that a completely biological and clinically relevant TEBV can be assembled exclusively from an individual's own cells.
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Cardiovascular tissue engineering introduced the prospect of a completely biological, living and autologous blood vessel produced in vitro to fill the crucial need for functional small-diameter conduits. Since Weinberg and Bell's landmark report 1 , the fundamental challenge in the field has been to produce a vessel with sufficient mechanical strength without relying upon permanent synthetic scaffolds. Using animal cells, two of the most promising tissue-engineering models have addressed this challenge 2, 3 (other models reviewed in ref. 4 ). Attempts to transition to human cells, however, underscored the difficulty of producing a clinically relevant conduit. Specifically, these human TEBVs did not provide requisite mechanical strength or required neonatal or juvenile cells [5] [6] [7] [8] . Although the use of human cells in low-pressure applications (o20 mmHg) has shown inspiring clinical success in pediatrics 9 , the promise of a tissue-engineered graft for adult arterial revascularization remains unrealized 10 .
Here we present the first TEBV suitable for autologous smalldiameter arterial revascularization in adults. This TEBV was assembled using a new method termed sheet-based tissue engineering. In this approach, fibroblasts are cultured in conditions that promote deposition of extracellular matrix to produce a cohesive sheet that can be detached from the culture flask. These sheets, comprised of living cells and a well-organized endogenous matrix, have probe-burst loads of 883 ± 42 gf and can be layered into three-dimensional tissues or organs with physiological mechanical strength 6, 11, 12 . This method achieves the goal of completely avoiding the use of exogenous biomaterials. Sheet-based tissue engineering also marks a departure from the dogma of cardiovascular tissue engineering by eliminating the need for smooth muscle cells (SMCs), whose early senescence is associated with decreased burst pressures in human models 7 .
RESULTS

TEBV production and short-term in vivo implantation
We constructed human age-and risk-matched TEBVs exclusively with cells isolated from individuals who had undergone vascular bypass surgery (n ¼ 6, age 65 ± 8 years, range 54-79). Fibroblast sheets were produced in as little as 6 weeks (43 ± 10 mm thick). Sheet thickness increased at a rate of 5 mm/week through 15 weeks. The TEBVs consisted of three components: a living adventitia, a decellularized internal membrane and an endothelium. We assembled the internal membrane by wrapping an 8-week-old fibroblast sheet around a Teflon-coated stainless-steel temporary support tube for three revolutions. After a maturation period of at least 10 weeks, the individual plies fused together to form a homogenous cylindrical tissue. We then dehydrated this tissue to form an acellular substrate for endothelial cell seeding. The internal membrane was also included to provide a barrier against cell migration toward the lumen. We formed the adventitia in a similar fashion, by wrapping a living sheet around the internal membrane. After a second maturation phase, we removed the steel tube, and seeded endothelial cells in the lumen of the living TEBV. We then subjected the vessel to pulsatile flow that increased from 3 ml/ min to 150 ml/min over a 3-d preconditioning period.
TEBVs with an internal diameter of 4.2 mm and a wall thickness of 407 ± 49 mm had mechanical properties that compared favorably with saphenous veins ( Table 1) and surpassed values reported for any other completely biological TEBV produced in vitro 2, 7, 11, 13, 14 . We xenografted human TEBVs in an immunosuppressed canine model for short-term evaluation ( Fig. 1) to confirm that these benchtop mechanical qualities would translate to the surgical setting. The vessels had positive handling characteristics and suturability. At 14 d, histological analysis showed the presence of a massive immune response (data not shown), confirming that only short-term time points can be studied in this xenogeneic model.
Long-term implantation study
We considered two approaches for longer-term in vivo evaluation of the TEBV: (i) to develop an autologous animal model or (ii) to implant the human model in an immunodeficient animal. As we (N.L., N.D. & T.N.M., unpublished data) and others have shown that the mechanical properties of TEBV are highly species dependent 2,7 , we concluded that the outcome of an autologous animal model was not likely to be representative of the performance of a human TEBV. Therefore, we implanted age-and risk-matched human TEBVs (1.5 mm internal diameter) in nude rats as abdominal interpositional grafts. A pilot group (n ¼ 13) received single-layer vessels (without an internal membrane). Overall patency was 85% with time points up to 225 d. Graft diameter, estimated using Doppler-ultrasound imaging, increased over time (data not shown), suggesting the need for increased mechanical strength. A second group (n ¼ 14) received two-layer TEBVs (with an internal membrane) to determine whether thicker and stronger vessels would maintain diameter. We explanted 12 patent vessels between 90 and 225 d (86% patency), showing graft incorporation into the surrounding tissue, no blood infiltration in the wall, a smooth lumen, intact anastomoses and no signs of lumen narrowing or aneurysm formation (Figs. 2 and 3) . Doppler-ultrasound evaluation suggested a stable diameter and we observed no mechanical failures. Overall patency for the two studies was 85%, which, considering the small diameter of the graft and the lack of postoperative antiplatelet therapy, clearly indicates the antithrombogenicity of the TEBV.
Histological analysis of the explanted TEBV at 90 d ( Fig. 2) showed tissue integration, formation of vasa vasorum and accumulation of cells on the luminal side of the internal membrane. Notably, the internal membrane was largely intact and still acellular. This suggests that the cell-synthesized extracellular matrix does not create an inflammatory response, which has been linked to stenosis 15 . The limited thickness of the 'neomedia' observed in the lumen of the TEBV is consistent with this hypothesis. The neomedia was highly cellular, composed of SMC-specific a-actin-positive cells intertwined with collagen fibers and developing elastic fibers, and was covered by a confluent endothelium (Fig. 2e-g ). At 6 months, the thicknesses of the neomedia and internal membrane were essentially unchanged ( Fig. 3a-c) . Graft diameter also appeared unchanged, as evidenced by the fact that the initial diameter mismatch to the o1 mm internal diameter abdominal aorta was still visible in the middle of the graft (Fig. 3d) . As a result of the exclusion of the SMC layer and the lack of immediate contractility, the remodeling to match the diameter of the native artery seems to be a slow process. The increased thickness and number of elastic fibers made the TEBV more closely resemble the native aorta (Fig. 3c) . Likewise, ultrastructural examination showed cell and extracellular matrix organization that were reminiscent of natural tissues (Fig. 3e,f) . Although circulating progenitor cells may have participated in the formation of the neomedia, SMCs migrating from the anastomoses were the probable source. Although this remodeling process is unlikely in grafts of clinically relevant length, SMC-specific a-actin-positive cells could be seen at the internal membrane-adventitia interface (Fig. 2h) . This suggests that SMClike cells can be recruited from the local environment, as is the case in vasculogenesis, or that implanted fibroblasts have differentiated into myofibroblasts 16 . This recruitment, which increased with time (data not shown), may be a load-induced response as the internal membrane gradually remodels. Expression of proteoglycan, which is often observed in pathological or developing tissues 17 , was seen throughout the TEBV before implantation (Fig. 2b) . Notably, 90 d after grafting, the TEBV was essentially devoid of proteoglycans, suggesting remodeling into a more physiological tissue (Fig. 2f) . Similarly, proteoglycans that were present in the newly formed neomedia at 90 d (Fig. 2f) were absent 3 months later, again suggesting a positive maturation process (Fig. 3b) .
Primate implantation
Although the small diameter of the rat model created a challenging environment (microsurgery and potential thrombosis), the circumferential wall stress, which is proportional to the diameter, was considerably lower than in clinically relevant TEBVs (3-6 mm internal diameter). To evaluate the TEBV in a more representative biomechanical environment, we implanted age-and risk-matched human TEBVs (4.2 mm internal diameter) as interpositional arterial grafts in three immunosuppressed cynomolgus macaques. We chose this model for its well-defined immunosuppression protocol which is commonly used for xenogeneic transplantation studies. All vessels were patent at explantation (n ¼ 1 at 6 weeks and n ¼ 2 at 8 weeks). Doppler-ultrasound, computed tomography-angiography (Fig. 4a) and necropsy (Fig. 4b) confirmed that the vessels were patent with smooth lumens, intact anastomoses and no sign of lumen narrowing or aneurysm formation. Histological observation showed a moderate immune response to the human tissue, limited formation of focal neomedia, formation of vasa vasorum and reendothelialization of an acellular and intact internal membrane (Fig. 4c-f) . Expression of proteoglycan was consistent with that observed in the rat model (Fig. 4e) , suggesting positive remodeling. Also similar to the rat model, SMC-specific a-actin-positive cells were seen at the internal membrane-adventitia interface (Fig. 4g) . Moreover, abundant a-actin staining was evident in the perivascular tissue. These observations suggest a possible mechanism for the long-term regeneration of contractile media. The mechanical requirements for completely biological tissueengineered grafts are not limited to demonstrating physiological burst pressure and compliance. It is also important that the graft be resistant to rapid degradation and fatigue-induced formation of aneurysms in vivo. Hence, we followed graft diameter via ultrasound imaging through the course of the primate study (Fig. 4h) . The constant diameter of the TEBV through 8 weeks indicates that the graft is mechanically stable during the phase of incorporation into the surrounding tissue. These data, coupled with positive histological observations and the absence of aneurysm formation in the longterm rat model, suggest that this TEBV has promise as a clinical graft. Clearly, the key to clinical efficacy will be the long-term remodeling responses in the completely autologous environment. Further xenogeneic or even autologous animal models would offer little insight into this remodeling process in humans. Therefore, autologous TEBVs are currently being evaluated clinically for peripheral arterial revascularization. Although the time to produce these TEBVs (B28 weeks) clearly precludes urgent clinical use, the vast majority of individuals who lack autologous vessels for revascularization can be identified months before surgical intervention. For example, individuals with hemodialysis-dependent end-stage renal disease, with coronary disease and chronic stable angina, or with peripheral vascular disease and claudication follow a well-defined disease progression and can have months-long preoperative waiting periods. Should initial clinical studies prove successful, future efforts will focus on reducing vessel production time and exploring the use of allogeneic TEBVs produced by sheet-based tissue engineering.
METHODS
Tissue culture. We extracted human skin fibroblasts as previously described 6 . For sheet production, we seeded cells at passage 3-5 at 10 4 cells/cm 2 on gelatincoated T-75 flasks and cultured them in DMEM supplemented with Ham F12 (20%), FetalClone bovine serum (20%), glutamine (2 mM), penicillin (100 U), streptomycin (100 mg/ml) and sodium ascorbate (500 mM). For maturation, we cultured vessels in 45 ml of the same medium, but decreased the concentration of sodium ascorbate to 250 mM. We extracted endothelial cells from saphenous veins and cultured them using endothelial cell growth factor and heparin as previously described 6 . We seeded endothelial cells at 10 5 cells/cm 2 in the TEBV and allowed them to adhere for 3 h. We changed all media three times per week.
Mechanical testing. We determined the mechanical strength of fibroblast sheets (n ¼ 6, 8 weeks of culture) using an indentation test. We loaded the center of a circular sheet, mounted on a force transducer, with a spherical tip (9 mm) of a probe at a rate of 20 mm/min until perforation. Force was digitally recorded. Other mechanical testing followed Association for the Advancement of Medical Instruments-American National Standards Institute (ANSI/AAMI) test standard VP20 with minor modifications for biological material. Burst pressure was achieved by increasing hydrostatic pressure within the vessel at a rate of 80 mmHg/min until failure. Pressure was digitally recorded. Clean longitudinal slits were the noted failure mechanism in TEBVs. Human mammary arteries were unused distal segments harvested during bypass surgery or vessels obtained at necropsy. We carefully dissected vessels to expose collaterals for ligation. We tested 3 right internal mammary artery segments and 10 left internal mammary artery segments from eight individuals (age 70 ± 10 years, range 61-87). We separated results into two groups: failures that seemed to be associated with the presence of a collaterals or wall defects (2,031 ± 872, n ¼ 8), and high-pressure failures that may reflect maximum material properties (4,225 ± 1368, n ¼ 5). To measure suture retention strength, we pulled (2 mm/s) a single throw of 5-0 prolene suture (2.2 ± 0.3-mm bite) through the TEBV segment, which was secured to a force transducer. We digitally recorded force. We obtained samples from the saphenous veins of two individuals, arteries from three individuals (two radial and three internal mammary). We calculated compliance (c) by measuring the change in internal diameter (d) as we varied the pressure (P) at 0.2 Hz between 80 and 120 mmHg. We used high-resolution digital images to determine TEBV outer diameter. The TEBV wall was assumed to be incompressible. Compliance was calculated using the equation:
Canine studies. We implanted human TEBVs (4.2 mm internal diameter, B6 cm long) following standard surgical techniques (n ¼ 5 grafts in four dogs) using 8-0 prolene. We administered immunosuppressive and antiplatelet therapies starting 48 h before surgery: cyclosporine (7.5 mg/kg), mycophenolate mofetil (20 mg/kg), methyl prednisolone (1 mg/kg per day), acetylsalicylic acid (325 mg per day) and clopidogrel (300 mg initial dose and 75 mg per day after surgery). This protocol was approved by the ethics committee of the Palo Alto Veterans Administration Hospital.
Nude rat studies. We anastomosed human TEBV (1.5 mm internal diameter, B7 mm long) using 10-0 prolene. In the pilot study (no internal membrane), animals received a single dose of antiplatelet agent (clopidogrel, 30 mg/kg, by mouth) 30 min before surgery. We harvested patent vessels at days 14 (g) Immunolabeling for SMC-specific a-actin stains a cell population at the internal membrane-adventitia interface (blue counterstain). Arrow indicates small blood vessel. (h) TEBV internal diameter was measured at the center of the graft by weekly Doppler-ultrasound examination of all animals. After an increase of about 5% associated with initial pressurization, the diameter remained constant for the duration of the study.
30 (n ¼ 1), 60 (n ¼ 1), 90 (n ¼ 5), 180 (n ¼ 1) and 225 (n ¼ 2). We explanted thrombosed vessels at days 3 (n ¼ 1) and 166 (n ¼ 1). In the second study (with internal membrane), we did not administer any antiplatelet drugs. We explanted patent vessels at days 90 (n ¼ 3), 120 (n ¼ 2), 180 (n ¼ 5) and 225 (n ¼ 2). We explanted thrombosed vessels at days 90 (n ¼ 1) and 180 (n ¼ 1). This protocol was approved by the Administrative Panel on Laboratory Animal Care of Stanford University.
Primate studies. We implanted human TEBVs (4.2 mm internal diameter, B3 cm long) using 8-0 prolene as end-to-end iliac (n ¼ 1) or abdominal aortic (n ¼ 2) interpositional grafts. We administered immunosuppressive and antiplatelet therapies starting 2 d before surgery: cyclosporine A (target plasma level of 250-300 ng/ml until end), mycophenolate mofetil (target plasma level of 1.5-2.0 mg/ml until end), rabbit antithymocyte globulin (5 mg/kg for 5 d), acetylsalicylic acid (10 mg/kg until day 14) and clopidogrel (0.5 mg/kg, until day 4 then wean over 10 d). We explanted patent grafts at 6 weeks (iliac) and 8 weeks (abdominal aorta). This protocol was approved by the Institutional Animal Care and Use Committee of the University of California, Davis and the California National Primate Research Center.
Tissue fixation and histology. We fixed grafts and control vessels in situ with cold phosphate-buffered paraformaldehyde 4% after a rinse with cold phosphate saline solution containing 5 mM Ca 2+ . Animals received heparin before being killed. In rats, we performed whole-body fixation, whereas we fixed only the target vasculature in dogs and primates. Antibodies against SMC a-actin and von Willebrand factor were shown with streptavidin-alkaline phosphatase LSAB 2 system (DakoCytomation #N1584, A0082) and a substrate kit (Vector Labs #SK-5100). We prepared transmission electronic microscopy samples as previously described 6 and further stained them with ruthenium red.
